Kymera Therapeutics, Inc. vs Pfizer, Inc. — Stock Comparison

KYMR
Kymera Therapeutics, Inc.
$80.71
▼ 0.44%
vs
PFE
Pfizer, Inc.
$26.33
▼ 1.39%
Q·Score Winner
Pfizer, Inc.
PFE6.5/10vs 5.8/10

Q·Score Breakdown

5.8
Neutral
Overall
6.5
Neutral
1.7
Quality
7.4
8.2
Health
7
6.1
Growth
5.6
6
Valuation
6.7
8.9
Sentiment
5.2
KYMR

96% of 23 covering analysts have a positive rating.

low return on equity (-27%).

PFE

Strong profitability with 12% net profit margins.

analyst sentiment is cautious.

Analyst Consensus

BUY
Target $118.86 (+47.3%)
21 analysts
HOLD
Target $29.00 (+10.2%)
27 analysts

Fundamentals

KYMR
PFE
Trailing P/E
19.4×
-19.9×
Forward P/E
9.4×
0.0%
Profit Margin
12.4%
0.0%
Gross Margin
75.8%
-27.1%
ROE
8.9%
55.5%
Revenue Growth
-1.2%
Earnings Growth
Beta
0.39
Price / Book
$6.6B
Market Cap
$149.8B
$28 – $103
52-Week Range
$22 – $29

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →